Cypherpunk Technologies Inc

CYPHNASDAQ · USD
1.87USD0.00 (-3.86%)
2610

Cypherpunk Technologies Inc (CYPH) Covered Calls

Cypherpunk Technologies Inc trades in the Asset Management industry with an IV Rank of 11.51%, low versus the past year. CYPH's highest covered call setup is the $2.50 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 33.69% out of the money with 7 days to expiration, a 36.36% return until expiration, and a 1,896.10% theoretical annualized return. Across the setups shown, annualized returns run from 309.95% to 1,896.10% at strikes between $2.00 and $7.50, with 7 to 216 days to expiration, as of Nov 13, 2026.

Read more

Running CYPH covered calls helps you generate income from Cypherpunk Technologies Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CYPH covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CYPH stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CYPH covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CYPH covered call is worth writing.

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

2026-11-2072.5033.690.050.1068.0036.361896.10-2.67+0.244460.05
2027-03-191267.50301.070.050.20568.00303.74879.89-2.67+0.1824,8710.15
2026-11-2072.006.950.150.2028.0014.97780.75-8.02+0.471630.05
2027-03-191265.00167.380.050.25318.00170.05492.62-2.67+0.237,2360.20
2026-12-31483.0060.430.050.25118.0063.10479.84-2.67+0.2900.20
2026-12-11282.5033.690.050.3568.0036.36474.03-2.67+0.3810.30
2026-11-27142.006.950.150.2528.0014.97390.37-8.02+0.49520.10
2027-03-191264.00113.900.150.50228.00121.93353.20-8.02+0.407690.35
2027-06-172165.50194.120.051.05368.00196.79332.54-2.67+0.5011.00
2027-06-172165.00167.380.300.50343.00183.42309.95-16.04+0.431980.20

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryAsset Management
  • SectorFinancial
  • IV Rank11.51% Low
  • Market cap (M$)202
  • 52 weeks high-55.37%
  • 52 weeks low281.63%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$4.15
    121.93% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-16
  • P/E3.31
  • Future P/E4.45
  • EPS (ttm)0.57
  • EPS growth next 5 years133.40%

As of Nov 13, 2026